<DOC>
	<DOCNO>NCT01412398</DOCNO>
	<brief_summary>This study regulatory post marketing surveillance Japan , local prospective observational study patient continuous cyclic peritoneal dialysis ( CCPD ) receive Fosrenol hyperphosphatemia . The objective study ass safety efficacy use Fosrenol clinical practice . This study also case investigation enrollment period one year , patient CCPD receive Fosrenol hyperphosphatemia recruit follow one year .</brief_summary>
	<brief_title>Fosrenol Post-marketing Surveillance Continuous Cyclic Peritoneal Dialysis Japan</brief_title>
	<detailed_description />
	<mesh_term>Hyperphosphatemia</mesh_term>
	<criteria>Patients undergo continuous cyclic peritoneal dialysis receive Fosrenol hyperphosphatemia Patients contraindicate base product label</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Fosrenol</keyword>
	<keyword>Hyperphosphatemia</keyword>
	<keyword>Continuous Cyclic Peritoneal Dialysis</keyword>
</DOC>